达雷妥尤单抗治疗新诊断的、复发/难治性的多发性骨髓瘤的研究进展
The Progress of Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
DOI: 10.12677/ACM.2022.12101296, PDF,    科研立项经费支持
作者: 宋文君*, 张 颢#：济宁医学院临床医学院，山东 济宁；济宁医学院附属医院血液科，山东 济宁
关键词: 达雷妥尤单抗；多发性骨髓瘤；CD38；临床疗效；Daratumumab； Multiple Myeloma； CD38； Clinical Efficacy
摘要: 多发性骨髓瘤(MM)主要是一种以浆细胞单克隆性增殖为特征的恶性血液系统肿瘤性疾病。在过去的十几年里，此病的治疗方法发生巨大变化，尽管过去传统的化疗取得了重大进展，但该病仍被认为是不可治愈的。近些年来，多种免疫疗法不断拓宽多发性骨髓瘤的治疗领域，逐渐取代了传统的化疗疗法。本文将综述免疫治疗CD38单抗(达雷妥尤单抗)的具体治疗机制和治疗新诊断的、复发/难治性的多发性骨髓瘤的最新研究进展。
Abstract: Multiple myeloma (MM) is primarily a malignant hematologic neoplastic disease characterized by monoclonal proliferation of plasma cells. The treatment of this disease has changed dramatically over the past decade or so, and despite significant advances in traditional chemotherapy in the past, the disease is still considered incurable. In recent years, multiple immunotherapies have been broadening the treatment of multiple myeloma, gradually replacing the traditional chemotherapy therapies. This article will review the specific therapeutic mechanisms of immunotherapy CD38 an-tibody (daratumumab) and recent research advances in the treatment of newly diagnosed, re-lapsed/refractory multiple myeloma.
文章引用：宋文君, 张颢. 达雷妥尤单抗治疗新诊断的、复发/难治性的多发性骨髓瘤的研究进展[J]. 临床医学进展, 2022, 12(10): 8963-8968. https://doi.org/10.12677/ACM.2022.12101296

参考文献

[1] Palumbo, A. and Anderson, K. (2011) Multiple Myeloma. The New England Journal of Medicine, 364, 1046-1060. [Google Scholar] [CrossRef] 
[2] Brigle, K. and Rogers, B. (2017) Pathobiology and Diagnosis of Multiple Myeloma. Seminars in Oncology Nursing, 33, 225-236. [Google Scholar] [CrossRef] [PubMed]
[3] Terhorst, C., et al. (1981) Biochemical Studies of the Human Thymocyte Cell-Surface Antigens T6, T9 and T10. Cell, 23, 771-780. [Google Scholar] [CrossRef] [PubMed]
[4] Reinherz, E.L., et al. (1980) Discrete Stages of Human In-trathymic Differentiation: Analysis of Normal Thymocytes and Leukemic Lymphoblasts of T-Cell Lineage. Proceedings of the National Academy of Sciences of the United States of America, 77, 1588-1592. [Google Scholar] [CrossRef] [PubMed]
[5] Malavasi, F., et al. (1994) Human CD38: A Glycoprotein in Search of a Function. Immunology Today, 15, 95-97. [Google Scholar] [CrossRef] [PubMed]
[6] Deaglio, S., et al. (2007) CD38 and ZAP-70 Are Functionally Linked and Mark CLL Cells with High Migratory Potential. Blood, 110, 4012-4021. [Google Scholar] [CrossRef] [PubMed]
[7] Malavasi, F., et al. (2011) CD38 and Chronic Lymphocytic Leukemia: A Decade Later. Blood, 118, 3470-3478. [Google Scholar] [CrossRef] [PubMed]
[8] Sanchez, L., et al. (2016) Daratumumab: A First-in-Class CD38 Monoclonal Antibody for the Treatment of Multiple Myeloma. Journal of Hematology & Oncology, 9, Article No. 51. [Google Scholar] [CrossRef] [PubMed]
[9] Marlein, C.R., et al. (2019) CD38-Driven Mitochondrial Traf-ficking Promotes Bioenergetic Plasticity in Multiple Myeloma. Cancer Research, 79, 2285-2297. [Google Scholar] [CrossRef] 
[10] Ghose, J., et al. (2018) Daratumumab Induces CD38 Inter-nalization and Impairs Myeloma Cell Adhesion. Oncoimmunology, 7, e1486948. [Google Scholar] [CrossRef] 
[11] Zhu, C., et al. (2020) Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Frontiers in Immunology, 11, Article No. 1771. [Google Scholar] [CrossRef] [PubMed]
[12] Viola, D., et al. (2021) Daratumumab Induces Mecha-nisms of Immune Activation through CD38+ NK Cell Targeting. Leukemia, 35, 189-200. [Google Scholar] [CrossRef] [PubMed]
[13] Moreau, P., et al. (2016) VTD Is Superior to VCD Prior to Inten-sive Therapy in Multiple Myeloma: Results of the Prospective IFM2013-04 Trial. Blood, 127, 2569-2574. [Google Scholar] [CrossRef] [PubMed]
[14] Moreau, P., et al. (2019) Bortezomib, Thalidomide, and Dex-amethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study. The Lancet, 394, 29-38. [Google Scholar] [CrossRef] 
[15] Voorhees, P.M., et al. (2020) Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial. Blood, 136, 936-945. [Google Scholar] [CrossRef] [PubMed]
[16] Abdallah, N. and Kumar, S.K. (2019) Daratumumab in Untreated Newly Diagnosed Multiple Myeloma. Therapeutic Advances in Hematology, 10. [Google Scholar] [CrossRef] [PubMed]
[17] Yimer, H., Melear, J., Faber, E., et al. (2018) Lyra: A Phase 2 Study of Daratumumab (Dara) plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM). Blood, 132, Article No. 152. [Google Scholar] [CrossRef] 
[18] Voorhees, P.M., et al. (2021) Daratumumab plus RVd for Newly Diagnosed Multiple Myeloma: Final Analysis of the Safety Run-In Cohort of GRIFFIN. Blood Advances, 5, 1092-1096. [Google Scholar] [CrossRef] [PubMed]
[19] Roussel, M., et al. (2020) Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab for Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma (CASSIOPEIA): Health-Related Quality of Life Outcomes of a Randomised, Open-Label, Phase 3 Trial. The Lancet Haematology, 7, e874-e883. [Google Scholar] [CrossRef] 
[20] Moreau, P., et al. (2021) Maintenance with Daratumumab or Observation Following Treatment with Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab and Autologous Stem-Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma (CASSIOPEIA): An Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 22, 1378-1390. [Google Scholar] [CrossRef] 
[21] Sonneveld, P. and Broijl, A. (2016) Treatment of Relapsed and Refractory Multiple Myeloma. Haematologica, 101, 396-406. [Google Scholar] [CrossRef] [PubMed]
[22] Attal, M., et al. (2019) Isatuximab plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low- Dose Dexamethasone in Patients with Relapsed and Refrac-tory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study. The Lancet, 394, 2096-2107. [Google Scholar] [CrossRef] 
[23] Lu, J., et al. (2021) Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clinical Lymphoma, Myeloma and Leukemia, 21, e699-e709. [Google Scholar] [CrossRef] [PubMed]
[24] Lonial, S., et al. (2016) Daratumumab Monotherapy in Patients with Treatment-Refractory Multiple Myeloma (SIRIUS): An Open-Label, Randomised, Phase 2 Trial. The Lancet, 387, 1551-1560. [Google Scholar] [CrossRef] 
[25] Nooka, A.K., et al. (2019) Clinical Efficacy of Daratumumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Myeloma: Utility of Re-Treatment with Daratumumab among Refractory Patients. Cancer, 125, 2991-3000. [Google Scholar] [CrossRef] [PubMed]
[26] Nooka, A.K., et al. (2019) Daratumumab in Multiple Myeloma. Cancer, 125, 2364-2382. [Google Scholar] [CrossRef] [PubMed]
[27] Dimopoulos, M.A., et al. (2016) Daratumumab, Lenalidomide, and Dexa-methasone for Multiple Myeloma. The New England Journal of Medicine, 375, 1319-1331. [Google Scholar] [CrossRef] 
[28] Palumbo, A., et al. (2016) Daratumumab, Bortezomib, and Dexa-methasone for Multiple Myeloma. The New England Journal of Medicine, 375, 754-766. [Google Scholar] [CrossRef] 
[29] Dimopoulos, M., et al. (2020) Carfilzomib, Dexamethasone, and Daratumumab versus Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CANDOR): Results from a Randomised, Multicentre, Open-Label, Phase 3 Study. The Lancet, 396, 186-197. [Google Scholar] [CrossRef] 
[30] Cho, S.F., Anderson, K.C. and Tai, Y.T. (2018) Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Frontiers in Immunology, 9, Article No. 1821. [Google Scholar] [CrossRef] [PubMed]
[31] Zannetti, B.A., et al. (2020) Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model. Cells, 9, Article No. 2666. [Google Scholar] [CrossRef] [PubMed]
[32] Ejaz, K., et al. (2021) Daratumumab: Beyond Multiple Myeloma. Transfusion Medicine Reviews, 35, 36-43. [Google Scholar] [CrossRef] [PubMed]

为你推荐